Mission, platform, and translational focus.
Overview
- AGEMICA is building an AI-native peptide lab focused on cancer and age-driven disease.
- The platform ranks peptide therapies and vaccines against multi-omics signatures, then validates candidates in ex vivo human cell models.
- Progress is staged through explicit gates: computational design, ex vivo readouts, selectivity testing, and IND-enabling work.
- The team combines AI engineering, computational biology, and Stanford- and Cambridge-affiliated scientific advisors.